2013
DOI: 10.1111/tid.12136
|View full text |Cite
|
Sign up to set email alerts
|

Treatment of BK virus‐associated hemorrhagic cystitis in pediatric hematopoietic stem cell transplant recipients with cidofovir: a single‐center experience

Abstract: CDV appears to be an effective and safe treatment for BKV-HC in pediatric HSCT recipients, but prospective trials are warranted to support its use.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

2
46
0

Year Published

2015
2015
2021
2021

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 48 publications
(48 citation statements)
references
References 30 publications
2
46
0
Order By: Relevance
“…To our knowledge, prospective studies of the treatment for BKV-HC are not available, and there are no standard treatment guidelines for post-HSCT HC. Treatment modalities are limited, particularly in children, partly owing to few reports on children receiving pharmaceutical and surgical treatments [4,[18][19][20]. Intravenous hydration with forced diuresis is conducted; however, this is supportive treatment only without reliable efficacy.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…To our knowledge, prospective studies of the treatment for BKV-HC are not available, and there are no standard treatment guidelines for post-HSCT HC. Treatment modalities are limited, particularly in children, partly owing to few reports on children receiving pharmaceutical and surgical treatments [4,[18][19][20]. Intravenous hydration with forced diuresis is conducted; however, this is supportive treatment only without reliable efficacy.…”
Section: Discussionmentioning
confidence: 99%
“…Intravenous hydration with forced diuresis is conducted; however, this is supportive treatment only without reliable efficacy. At present, cidofovir is the only commercially available antiviral agent against BKV, and its efficacy for BKV-HC has been investigated only in retrospective studies [19][20][21]. In the report from the European Group for Blood and Marrow Transplantation, intravenous or intravesical cidofovir was administered to 62 patients with BKV-HC [21].…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Mostly given at 5 mg/kg/week in both primary or secondary pre-emptive therapy for CMV infection with response rates of 50% for CMV disease and 62% to 66% for CMV infection, significant renal toxicities were reported [39]. Several applications of CDF against different viral pathogens in pediatric patients [40] have been reported in recent years, in particular against adenovirus [41], BK virus-associated hemorrhagic cystitis [42,43] and poxvirus [44].…”
Section: Cidofovir (Cdf) -The Last Resortmentioning
confidence: 99%
“…Consequently, children undergoing HSCT are at profound risk for serious and potentially fatal viral infections. Viruses that commonly complicate HSCT include adenoviruses, cytomegalovirus (CMV), herpes simplex virus (HSV), human herpesvirus 6 (HHV-6), BK virus, and other community-acquired respiratory and gastrointestinal (GI) viruses (2)(3)(4)(5)(6). Furthermore, the need for protracted antiviral therapy due to impaired immune clearance increases the risk of antiviral resistance to first-line agents (4).…”
mentioning
confidence: 99%